Results 41 to 50 of about 18,746 (183)

Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods

Frontiers in Psychiatry, 2022
BackgroundCognitive side-effects are an important reason for the limited use of electroconvulsive therapy (ECT). Cognitive side-effects are heterogeneous and occur frequently in older persons.
Marieke J. Henstra, Marieke J. Henstra, Marieke J. Henstra, Thomas C. Feenstra, Thomas C. Feenstra, Rob M. Kok, Harm-Pieter Spaans, Eric van Exel, Eric van Exel, Eric van Exel, Eric van Exel, Annemiek Dols, Annemiek Dols, Annemiek Dols, Annemiek Dols, Annemiek Dols, Mardien Oudega, Mardien Oudega, Mardien Oudega, Mardien Oudega, Anton C. M. Vergouwen, Adriano van der Loo, Pierre M. Bet, Stephan A. Loer, Merijn Eikelenboom, Merijn Eikelenboom, Pascal Sienaert, Simon Lambrichts, Filip Bouckaert, Judith E. Bosmans, Judith E. Bosmans, Nathalie van der Velde, Nathalie van der Velde, Aartjan T. F. Beekman, Aartjan T. F. Beekman, Aartjan T. F. Beekman, Max L. Stek, Didi Rhebergen, Didi Rhebergen, Didi Rhebergen   +39 more
doaj   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Rivastigmine prevents injury induced by ischemia and reperfusion in rat liver [PDF]

Acta Cirúrgica Brasileira, 2018
Purpose: To evaluate whether pre-treatment with rivastigmine is able to attenuate the I/R induced lesions in rat liver. Methods: SHAM animals or those submitted to I/R, non-treated or pre-treated with rivastigminine (2mg/kg) either 50 or 15 minutes ...
Agnaldo Bruno Chies, Paula Carolina Grande Nakazato, Maria Angélica Spadella, Patrícia Zorzi, Maria Cecília Jordani Gomes, Luiz Augusto Carneiro D’Albuquerque, Orlando Castro-e-Silva   +6 more
doaj   +1 more source

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease [PDF]

, 2014
Background: Alzheimer's disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon®, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated ...
Davide V. Moretti, Giovanni B. Frisoni, Giuliano Binetti, Orazio Zanetti   +3 more
core   +2 more sources

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis [PDF]

, 2003
Background Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer's Disease (AD) in Canada. In making choices amongst these drugs, one should consider their clinical merits and their
Jaime Caro, null null, Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, Wissam El-Hadi   +5 more
core   +2 more sources

Ambient technology in epilepsy clinical practice

Epilepsia Open, EarlyView.
Abstract The utilization of large language model‐based artificial intelligence (AI) in the field of neurology has gained attention as a viable tool to enhance and assist providers with processes ranging from scheduling patients to providing preliminary interpretations of testing results, pending orders, and documenting encounters. Epileptologists could
Haania Kakwan, Justin F. Rousseau, Lidia M. Moura, Irfan S. Sheikh   +3 more
wiley   +1 more source

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil

Brazilian Journal of Psychiatry, 2018
Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer’s disease (AD) from the perspective of the Brazilian Unified Health System.
Luciana R. da Silva, Cid M.M. Vianna, Gabriela B.G. Mosegui, Antônio A.F. Peregrino, Valeska Marinho, Jerson Laks   +5 more
doaj   +1 more source

Improvement in delirium and visuospatial function after rivastigmine in antimuscarinic toxicity: a case report

Toxicology Communications, 2023
Treatment of antimuscarinic toxicity has become more difficult in the United States due to an ongoing national shortage of physostigmine. Rivastigmine has emerged as an alternative, off-label therapy due to its similar mechanism of action as a reversible,
Matthew S. Correia, Robert G. Hendrickson   +1 more
doaj   +1 more source

NICE 2011 recommendations on the management of Alzheimer’s disease by acetylcholinesterase inhibitors and memantine [PDF]

, 2011
The National Institute of Clinical Excellence (NICE) has lately overturned its decision to restrict the use of acetycholinesterase inhibitors and memantine in patients diagnosed with Alzheimer’s disease (AD).
Scerri, Charles
core